U.N. member states agree to drug control policy

United Nations member states on Thursday agreed to a 10-year renewal of their anti-drug policy amid criticism that the strategy has contributed to the spread of HIV, Reuters reports.

European Union delegates to the United Nations Commission for Narcotic Drugs convention expressed frustration about a lack of harm-reduction measures that aim to prevent the spread of HIV/AIDS and other bloodborne diseases in policy, according to Reuters. Critics said the lack of harm-reduction measures, such as needle-exchange programs, has helped fuel the spread of HIV/AIDS and allowed drug cartels to flourish, Reuters reports.

Delegates at the conference noted an "alarming" increase in HIV among injection drug users, Reuters reports. German Ambassador Ruediger Luedeking at the conference argued that harm-reduction intends to address health risks associated with injection drug use and does not aim to replace drug-control efforts. Countries opposed to harm reduction -- which include China, Italy, Japan, Russia and the U.S. -- have said such efforts legitimize injection drug use and undermine law enforcement. According to Reuters, harm-reduction is common in Western countries and Latin America but is prohibited in Russia, which has been "hard-hit" by an HIV epidemic among IDUs (Heinrich, Reuters, 3/12).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Affordability and supply remain critical to the success of long-lasting HIV drug